Bayer shareholders have handed management a powerful financial weapon. At the company’s annual general meeting, they approved a blanket authorization to issue new shares worth up to €7 billion. The move is a direct bet on ending the glyphosate litigation nightmare — but the timing remains uncertain.
The Leverkusen-based group has no immediate plans to tap the market. The cash would only flow if an out-of-court settlement in the Roundup dispute materializes. That scenario now hinges on a pivotal hearing at the US Supreme Court on April 27, where Bayer will argue that federal law preempts state-level failure-to-warn claims. The US Department of Justice has already backed this position.
Lobbying Blitz Alongside Legal Strategy
The legal push is running in parallel with a political campaign. Investigative platform EXPOSEDbyCMD revealed that Bayer quietly launched the “Modern Ag Alliance” in 2024. The group is pressing Congress to insert a Roundup immunity clause into the next Farm Bill — a legislative end-run around tens of thousands of open cancer lawsuits.
Bayer is also leaning on a Trump-era executive order mandating domestic production of crop protection chemicals. The company has pledged to comply, adding another layer to its multi-front defense.
Shareholder Mood: Between Hell and Hope
The AGM atmosphere remained tense despite the authorization vote. Marc Tüngler of the German Association for the Protection of Securities Holdings captured the sentiment, describing investors as trapped “between hell and hope.” The Monsanto acquisition hangover continues to weigh heavily.
Should investors sell immediately? Or is it worth buying Bayer?
Shareholders did approve a dividend of €0.11 per share for the past year, unchanged from the previous payout. Management also reaffirmed its 2025 outlook: revenue of up to €47 billion and operating profit around €10 billion.
Pharma Pipeline Offers a Bright Spot
Beyond the courtroom drama, Bayer’s pharmaceuticals division delivered encouraging news. A Phase III trial showed that the drug Asundexian reduced stroke risk by 26%. The US Food and Drug Administration has granted it fast-track status, raising hopes for a future revenue driver.
The stock closed Thursday at €40.04, hovering near its 50-day moving average. Over the past twelve months, shares have climbed roughly 78%, though the secondary source pegs the gain at 82%. Net debt fell 8.5% to just under €29.8 billion by end-2025.
The Calendar That Defines Bayer’s Future
The coming days will shape the company’s trajectory for years. Friday’s AGM vote on profit appropriation is procedural. Monday’s Supreme Court arguments are existential. A ruling in Bayer’s favor could strip the legal foundation from over 65,000 pending cases. A Missouri settlement package worth around $7 billion has already received preliminary approval.
The final verdict from Washington is expected by June. Until then, the share price will dance to the rhythm of legal filings and court schedules. The next operational update comes with the quarterly report on May 12, but all eyes remain fixed on the Supreme Court bench.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from April 24 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 24.
Bayer: Buy or sell? Read more here...
